{
    "medicine_id": "241fd8b738fcb617f687452bbdb46b437c611eaf",
    "platform_id": "DB05332",
    "metadata": {
        "name": "Nplate 250 \u03bcg Injection powder for solution",
        "composition": "250 \u03bcg Romiplostim",
        "clinical_particulars": {
            "therapeutic_indications": "Treatment of chronic immune thrombocytopenic purpura",
            "contraindications": {
                "disease": "The most common adverse reactions 5 higher patient incidence in Nplate versus placebo are arthralgia dizziness insomnia myalgia pain in extremity abdominal pain shoulder pain dyspepsia and paresthesia Headache was the most commonly reported adverse reaction that did not occur at 5 higher patient incidence in Nplate versus placebo LD50 980 mg kg",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Responses to platelet increase varies between patients thus indicating a need for individualization of dose However a dose dependent increase in platelet counts have been observed in clinical trials Does not affect platelet destruction",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00531",
                        "description": "The risk or severity of pulmonary toxicity can be increased when Romiplostim is combined with Cyclophosphamide"
                    },
                    {
                        "drugbank-id": "DB00309",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vindesine"
                    },
                    {
                        "drugbank-id": "DB00361",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vinorelbine"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vincristine"
                    },
                    {
                        "drugbank-id": "DB00570",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vinblastine"
                    },
                    {
                        "drugbank-id": "DB05168",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vintafolide"
                    },
                    {
                        "drugbank-id": "DB11641",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vinflunine"
                    },
                    {
                        "drugbank-id": "DB13374",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vincamine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}